A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)
Completed
- Conditions
- Nephrology
- Registration Number
- NCT00189501
- Lead Sponsor
- Amgen
- Brief Summary
Objectives include description of current practices; assessment over time of K/DOQI goals, clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and the impact of Sensipar® on these parameters
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
- 3 month history of Stage 4 or Stage 5 CKD
- A PTH value within 3 months of enrollment
- If relevant, completion of Sensipar® study prior to enrolling in Registry
Exclusion Criteria
- Females who are pregnant or breast feeding
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Sensipar® in managing secondary hyperparathyroidism in CKD patients?
How does Sensipar® compare to standard-of-care calcimimetics in CKD-related secondary hyperparathyroidism outcomes?
Which biomarkers correlate with treatment response to Sensipar® in advanced chronic kidney disease registries?
What adverse events are associated with long-term Sensipar® use in CKD patients and how are they managed?
Are there combination therapies involving Sensipar® and vitamin D analogs for CKD-mineral bone disorder management?